Genta Incorporated announced initiation of treatment in a Phase 2 trial of tesetaxel in advanced melanoma. The study will examine the effects of tesetaxel in patients with advanced melanoma who have developed progressive disease after treatment with a single first-line regimen. Endpoints of the study include response rate, durable response, disease control, progression-free survival, and safety.
Tesetaxel is a novel, orally absorbed, semi-synthetic taxane. Tesetaxel was developed with a goal of maintaining the high antitumor activity of the taxane drug class while eliminating infusion reactions associated with IV taxanes (eg, paclitaxel and docetaxel), reducing neuropathy, and increasing patient convenience. The oral route also enables the development of novel schedules that may expand dosing options when tesetaxel is used alone or in combination with other anticancer drugs, including “all oral” chemotherapy programs.
For more information call (908) 286-9800 or visit www.genta.com.